AZTR
Azitra Inc
NYSE MKT: AZTR · HEALTHCARE · BIOTECHNOLOGY
$0.25
+0.52% today
Updated 2026-04-29
Market cap
$3.56M
P/E ratio
—
P/S ratio
239.97x
EPS (TTM)
$-2.25
Dividend yield
—
52W range
$0 – $2
Volume
14.7M
Azitra Inc (AZTR) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-57.6%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+44.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-11.3%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-12.9%
2025-11-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-27 | $-1.17 | -265.6% | $0.18 | $0.16 | -9.7% |
| 2025-11-12 | $-0.67 | +13.0% | $0.40 | $0.35 | -12.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.32 | $-1.17 | -265.6% | — | — |
| 2025-09-30 | $-0.77 | $-0.67 | +13.0% | — | — |
| 2025-06-30 | $-1.40 | $-1.20 | +14.3% | — | — |
| 2025-03-31 | — | $-0.23 | — | — | — |
| 2024-12-31 | $-3.33 | $-2.09 | +37.2% | $7.49M | +8225.0% |
| 2024-09-30 | $-3.20 | $-3.30 | -3.1% | — | — |
| 2024-06-30 | $-21.45 | $-18.25 | +14.9% | $7500.00 | -95.6% |
| 2024-03-31 | — | $-4.36 | — | $90000.00 | — |
| 2023-12-31 | $-35.96 | $27.97 | +177.8% | $90000.00 | — |
| 2023-09-30 | — | $-0.16 | — | $310700.00 | — |
| 2023-06-30 | — | $-83.78 | — | $172000.00 | — |
Frequently asked questions
Has Azitra Inc beaten earnings estimates?
Azitra Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -57.6% over the last 3 quarters.
How does AZTR stock react to earnings?
AZTR stock has moved an average of -11.3% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.